# Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

> **NCT02242331** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 19805 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Micardis®

## Key facts

- **NCT ID:** NCT02242331
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2002-05
- **Final completion:** —
- **Target enrollment:** 19805 (ACTUAL)
- **Last updated:** 2014-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242331, "Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02242331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*